Associate Professor Michael Wiese

Associate Professor in Pharmacotherapeutics School of Pharmacy and Medical Sciences

City West Campus (HB6-27)
tel +61 8 830 22312

email Michael.Wiese@unisa.edu.au

Research Degree Supervisor

About me

Welcome to my home page. I am a registered pharmacist and worked in practice for 10 years prior to joining the staff at the University in 2008. I am interested in the clinical use of medicines, and my predominant teaching role is in the pharmacotherapeutics subjects of the 3rd year of the Undergraduate Pharmacy Program.

My primary research interests are personalised medicine (including pharmacogenomics and drug concentration effect relationships, particularly in patients with rheumatoid arthritis), drug allergy and deprescribing (the process of ceasing redundant medications).

School of Pharmacy and Medical Sciences

With standout facilities and strong industry links, the School prepares students for careers in health and medical science.

Tweets by @UniversitySA

Research

Research themes

An age friendly world
Cancer
Healthy futures

Research focus

Clinical Sciences
Public Health and Health Services
Immunology
Pharmacology and Pharmaceutical Sciences
Medical and Health Sciences

Highlights

Personalised medicine, primarily improving the efficiency of drug dosage regimens according to patient specific factors, and the use of therapeutic drug monitoring to improve efficacy and reduce toxicity of medications.
Drug Allergy, including the development of in vitro diagnostic techniques,Identification of strategies to cease redundant medications
The use of venom immunotherapy to desensitise patients who are allergic to ant venom, including laboratory invetigations to identify patients at risk of failure of therapy or of side effects.

Research

Outputs

Research since 2008 is shown below. To see earlier years visit ResearcherID or Scopus

Open access indicates that an output is open access.

Journal Articles

Year	Output
2018	Polasek, TM, Tucker, GT, Sorich, MJ, Wiese, MD, Mohan, T, Rostami-Hodjegan, A, Korprasertthaworn, P, Perera, V & Rowland, A 2018, 'Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation', British journal of clinical pharmacology, vol. 84, no. 3, pp. 462-476. 1 55
2018	Soo, JY, Wiese, MD, Berry, MJ & Morrison, JL 2018, 'Does poor fetal growth influence the extent of fetal exposure to maternal medications?', Pharmacological research, vol. 130, pp. 74-84. 1
2018	Soo, JY, Wiese, MD, Berry, MJ, McMillen, IC & Morrison, JL 2018, 'Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period', Pharmacological research, vol. 134, pp. 68-78.
2018	Wanandy, T, Wilson, R, Gell, D, Rose, HE, Gueven, N, Davies, NW, Brown, SG & Wiese, MD 2018, 'Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach', Clinical and experimental allergy, vol. 48, no. 9, pp. 1222-1234.
2017	Dias, MM, Sorich, MJ, Rowland, A, Wiese, MD & McKinnon, RA 2017, 'The routine clinical use of pharmacogenetic tests: what it will require?', Pharmaceutical research, online, pp. 1-7. 3 3 3
2017	Hopkins, AM, Moghaddami, M, Foster, DJ, Proudman, SM, Upton, RN & Wiese, MD 2017, 'Intracellular CD3(+) T lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration', Drug metabolism and disposition, vol. 45, no. 1, pp. 8-16. 3 2
2017	Hopkins, AM, Rowland, A, Kichenadasse, G, Wiese, MD, Gurney, H, McKinnon, RA, Karapetis, CS & Sorich, MJ 2017, 'Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers', British journal of cancer, vol. 117, no. 7, pp. 913-920. Open access 9 8 7
2017	Hopkins, AM, Wiese, MD, O'Doherty, CE & Proudman, SM 2017, 'Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis', Clinical rheumatology, vol. 36, no. 4, pp. 791-798. 1 1
2017	Mangoni, AA, Baghdadi, LR, Shanahan, EM, Wiese, MD, Tommasi, S, Elliot, D & Woodman, RJ 2017, 'Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study', Therapeutic advances in musculoskeletal disease, vol. 9, no. 9, pp. 213-229. 5 4
2017	Maundrell, A, Lester, S, Rischmueller, M, Hill, C, Cleland, LG, Blumbergs, P, Wiese, M & Limaye, V 2017, 'The PTPN22 gene is associated with idiopathic inflammatory myopathy', Muscle and nerve, vol. 55, no. 2, pp. 270-273. 2 2
2017	Rowland, A, Van Dyk, M, Mangoni, AA, Miners, JO, McKinnon, RA, Wiese, MD, Rowland, A, Kichenadasse, G, Gurney, H & Sorich, MJ 2017, 'Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure', Expert opinion on drug metabolism and toxicology, vol. 13, no. 1, pp. 31-49. 15 13 2
2017	Tait, PA, Cheung, WH, Wiese, M & Staff, K 2017, 'Improving community access to terminal phase medicines in Australia: Identification of the key considerations for the implementation of a 'core medicines list'', Australian journal of primary health, vol. 23, no. 4, pp. 373-378. 7
2017	Wabe, N, Lee, A, Wechalekar, MD, McWilliams, L, Proudman, SM & Wiese, M 2017, 'Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users', Rheumatology international, vol. 37, no. 6, pp. 897-904. 2 2 1
2017	Wabe, N, Wojciechowski, J, Wechalekar, MD, Cleland, LG, McWilliams, L, Lee, A, Proudman, S & Wiese, MD 2017, 'Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy', International Journal of Rheumatic Diseases, vol. 20, no. 10, pp. 1447-1456.
2017	Wanandy, T, Dwyer, H, McLean, L, Davies, N, Nichols, D, Gueven, N, Brown, S & Wiese, M 2017, 'Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy', Clinical and Experimental Allergy, vol. 47, no. 11, pp. 1478-1490.
2017	Wimmer, BC, Cross, AJ, Jokanovic, N, Wiese, MJ, George, J, Johnell, K, Diug, B & Bell, JS 2017, 'Clinical outcomes associated with medication regimen complexity in older people: a systematic review', Journal of the American Geriatrics Society, vol. 65, no. 4, pp. 747-753. 16 13 41
2017	Wojciechowski, J, Upton, RN, Foster, DJ, Wiese, MD & Mould, DR 2017, 'Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies', AAPS Journal, online, pp. 1-12. 4 4 4
2016	Hopkins, AM, Proudman, SM, Vitry, A, Sorich, MJ, Cleland, LG & Wiese, MD 2016, 'Ten years of Publically Funded Biological Disease Modifying Antirheumatic Agents in Australia', Medical Journal of Australia, vol. 204, no. 2, pp.64-68. 5 2 1
2016	Lester, S, Hewitt, AW, Ruediger, CD, Bradbury, L, De Smit, E, Wiese, MD, Black, R, Harrison, A, Jones, G, Littlejohn, GO, Merriman, TR, Shenstone, B, Smith, MD, Rischmueller, M, Brown, MA & Hill, CL 2016, 'PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis', RMD open, vol. 2, no. 1, article no. e000246, pp. 1-3. Open access 4
2016	Polasek, TM, Ambler, K, Scott, HS, Sorich, MJ, Kaub, PA, Rowland, A, Wiese, MD & Kichenadasse, G 2016, 'Targeted pharmacotherapy after somatic cancer mutation screening', F1000Research, vol. 5, article no. 1551, pp. 1-8. Open access 4 1
2016	Rowland, A, Dias, MM, Wiese, MD, Kichenadasse, G, McKinnon, RA, Karapetis, CS & Sorich, MJ 2016, 'Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours', European Journal of Cancer, vol. 55, pp. 122-130. 10 11 2
2016	Shahnam, A, Ridha, Z, Wiese, MD, Kichenadasse, G & Sorich, Mj 2016, 'Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis', Pharmacogenomics, vol. 17, no. 15, pp. 1725-1732. 4 2 15
2016	Wabe, N & Wiese, MD 2016, 'Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy', Journal of evaluation in clinical practice, vol. 23, no. 3, pp. 486-493. 4 2
2016	Wabe, N, Sorich, M, Wechalekar, M, Cleland, L, McWilliams, L, Lee, A, Hall, C, Spargo, L, Metcalf, R, Proudman, S & Wiese, M 2016, 'Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?', International journal of clinical practice, vol. 70, no. 4, pp. 340-350. 2 2 11
2016	Wabe, NT, Sorich, MJ, Wechalekar, MD, Cleland, LG, McWilliams, L, Lee, AT, Spargo, LD, Metcalf, RG, Hall, C, Proudman, S & Wiese, MD 2016, 'Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: Results from an Australian early arthritis cohort', Journal of rheumatology, vol. 43, no. 9, pp. 1643-1649. 3 3 4
2016	Wimmer, BC, Bell, JS, Fastbom, J, Wiese, MD & Johnell, K 2016, 'Medication regimen complexity and number of medications as factors associated with unplanned hospitalizations in older people: a population-based cohort study', Journals of gerontology - series A : biological sciences and medical sciences, vol. 71, no. 6, pp. 831-837. Open access 12 11 5
2016	Wimmer, BC, Bell, JS, Fastbom, J, Wiese, MD & Johnell, K 2016, 'Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study', Annals of Pharmacotherapy, vol. 50, no. 2, pp. 89-95. Open access 15 14 36
2016	Wojciechowski, J, Wiese, MD, Proudman, SM, Foster, DJ & Upton, RN 2016, 'A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity', British Journal of Clinical Pharmacology, vol. 81, no. 6, pp. 1046-1057. Open access
2015	Hopkins, A, Wiese, M, Proudman, S, O'Doherty, C, Foster, D & Upton, R 2015, 'Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients', CPT: pharmacometrics & systems pharmacology, vol. 4, no. 6 pp. 362-371. 7 7
2015	Hopkins, AM, Wiese, MD, Proudman, SM, O'Doherty, CE, Upton, RN & Foster, DJR 2015, 'Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis', British journal of clinical pharmacology, vol. 81, no. 1, pp. 113-123. Open access 8 5
2015	Mohamed, HJ, Sorich, MJ, Kowalski, SM, McKinnon, R, Proudman, SM, Cleland, L & Wiese, MD 2015, 'The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies - a systematic review', European journal of clinical pharmacology, v 71, no.4, pp. 411-423. Open access 6 4
2015	Reeve, E, Andrews, JM, Wiese, MD, Hendrix, I, Roberts, MS & Shakib, S 2015, 'Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors', The annals of pharmacotherapy, vol. 49, no. 1, pp. 29-38. 31 23 8
2015	Reeve, E, Wiese, MD & Mangoni, AA 2015, 'Alterations in drug disposition in older adults', Expert opinion on drug metabolism & toxicology, vol. 11, no. 4, pp. 491-508. 19 18 3
2015	Rowland, A, Dias, M, Wiese, M, Kichenadasse, G, McKinnon, R, Karapetis, C & Sorich, M 2015, 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer', British journal of cancer, vol. 112, pp. 1888-1894. Open access 79 73 12
2015	Sorich, M, Wiese, M, Rowland, A, Kichenadasse, G, McKinnon, R & Karapetis, C 2015, 'Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trails', Annals of oncology. 164 155 9
2015	Wabe, N, Sorich, M, Wechalekar, M, Cleland, L, McWilliams, L, Lee, A, Spargo, L, Metcalf, R, Hall, C, Proudman, S & Wiese, M 2015, 'Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years', Arthritis Research and Therapy, vol.17, pp. 1-14. Open access 9 9
2015	Wanandy, T, Gueven, N, Davies, NW, Brown, SG & Wiese, M 2015, 'Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula', Toxicon, vol. 98, no. , pp. 54-61. 14 14 5
2015	Wimmer, BC, Johnell, K, Fastbom, J, Wiese, MD & Bell, SJ 2015, 'Factors associated with medication regimen complexity in older people: a cross-sectional population-based study', European journal of clinical pharmacology, vol. 71, no. 9, pp. 1099-1108. 13 13 4
2014	Hopkins, AM, O'Doherty, C, Foster, D, Suppiah, V, Upton, R, Spargo, L, Cleland, L, Proudman, S & Wiese, M 2014, 'The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity', Journal of clinical pharmacy and therapeutics, vol. 39, no. 5, pp. 555-560. 6 5 1
2014	Hopkins, AM, O'Doherty, CE, Foster, DJR, Upton, RN, Proudman, SM & Wiese, MD 2014, 'Individualization of leflunomide dosing in rheumatoid arthritis patients', Personalized medicine, vol. 11, no. 4, pp. 449-461. 5 5 1
2014	Reeve, E & Wiese, MD 2014, 'Benefits of deprescribing on patients' adherence to medications', International journal of clinical pharmacy, vol. 36, no. 1, pp. 26-29. 32 25 8
2014	Reeve, E, Shakib, S, Hendrix, I, Roberts, MS & Wiese, MD 2014, 'Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process', British journal of clinical pharmacology, vol. 78, no. 4, pp. 738-747. Open access 66 56 36
2014	Reeve, E, Shakib, S, Hendrix, I, Roberts, MS & Wiese, MD 2014, 'The benefits and harms of deprescribing', Medical journal of Australia, vol. 201, no. 7, pp. 386-389. 38 23 7
2014	Russo, PAJ, Banovic, T, Wiese, MD, Whyte, A, Whyte, AF & Smith, WB 2014, 'Systemic allergy to EDTA in local anesthetic and radiocontrast media', Journal of allergy and clinical immunology: in practice, vol. 2, no. 2, pp. 225-229. 2 2
2014	Sorich, MJ, Rowland, A, McKinnon, RA & Wiese, MD 2014, 'CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with Clopidogrel : a meta-analysis', Circulation : Cardiovascular genetics, vol. 7, no. 6, pp. 895-902. Open access 30 29 1
2014	Stone, SF, Phillips, EJ, Wiese, MD, Heddle, RJ & Brown, SG 2014, 'Immediate-type hypersensitivity drug reactions', British journal of clinical pharmacology, vol. 78, no. 1, pp. 1-13. Open access 13 11 8
2014	Wiese, M, Alotaibi, N, O'Doherty, C, Sorich, M, Suppiah, V, Cleland, L & Proudman, S 2014, 'Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis', Pharmacogenomics journal, vol. 14, pp. 350-355. 12 11
2014	Wiese, MD, Suppiah, V & O'Doherty, C 2014, 'Metabolic and safety issues for multiple sclerosis pharmacotherapy: opportunities for personalised medicine', Expert opinion on drug metabolism & toxicology, vol. 10, no. 8, pp. 1145-1159. 2 1 1
2014	Wimmer, BC, Dent, E, Bell, JS, Wiese, MD, Chapman, I, Johnell, K & Visvanathan, R 2014, 'Medication regimen complexity and unplanned hospital readmissions in older people', The annals of pharmacotherapy, vol. 48, no. 9, pp. 1120-1128. 22 16 10
2014	Wimmer, BC, Dent, E, Visvanathan, R, Wiese, MD, Johnell, K, Chapman, I & Bell, JS 2014, 'Polypharmacy and medication regimen complexity as factors associated with hospital discharge destination among older people: a prospective cohort study', Drugs and aging, vol. 31, no. 8, pp. 623-630. 14 14 5
2014	Wojciechowski, J, Wiese, MD, Proudman, SM, Foster, DJ & Upton, RN 2014, 'A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine', British journal of clinical pharmacology, 777;vol. 79, no. 5, pp. 777-788. Open access 3 2
2013	Polasek, TM, Patel, F, Jensen, BP, Sorich, MJ, Wiese, MD & Doogue, MP 2013, 'Predicted metabolic drug clearance with increasing adult age', British journal of clinical pharmacology, vol. 75, no. 4, pp. 1019-1028. 19 17 1
2013	Reeve, E, Shakib, S, Hendrix, I, Roberts, MS & Wiese, MD 2013, 'Development and validation of the patients' attitudes towards deprescribing (PATD) questionnaire', International journal of clinical pharmacy, vol. 35, no. 1, pp. 51-56. 23 22
2013	Reeve, E, To, J, Hendrix, I, Shakib, S, Roberts, MS & Wiese, MD 2013, 'Patient barriers to and enablers of deprescribing: a systematic review', Drugs and aging, vol. 30, no. 10, pp. 793-807. 104 93 44
2013	Reeve, E, Wiese, MD, Hendrix, I, Roberts, MS & Shakib, S 2013, 'People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe', Journal of the American Geriatrics Society, vol. 61, no. 9, pp. 1508-1514. 63 51 13
2013	Russo, PA, Wiese, MD, Smith, MD, Ahern, MJ, Barbara, JA & Shanahan, EM 2013, 'Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study', The annals of pharmacotherapy, vol. 47, no. 3, pp. 15-27. 6 7 2
2013	Sorich, M, Polasek, T & Wiese, M 2013, 'Challenges and limitations in the interpretation of systematic reviews : making sense of clopidogrel and CYP2C19 pharmacogenetics', Clinical pharmacology and therapeutics, vol. 94, no. 3, pp. 376-382. 15 15
2013	Sorich, MJ, Horowitz, JD, Sorich, W, Wiese, MD, Pekarsky, B & Karnon, JD 2013, 'Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia', Pharmacogenomics, vol. 14, no. 16, pp. 2013-2021. 15 13 1
2013	Sorich, MJ, Wiese, MD, O'Shea, RL & Pekarsky, B 2013, 'Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia', Pharmacoeconomics, vol. 31, no. 5, pp. 377-391. 13 12 2
2013	Wahab, IA, Pratt, NL, Wiese, MD, Kalisch, LM & Roughead, EE 2013, 'The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection', Pharmacoepidemiology and drug safety, vol. 22, no. 5, pp. 496-502. 22 23 1
2013	Wiese, MD, Rowland, A, Polasek, TM, Sorich, MJ & O'Doherty, C 2013, 'Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis', Expert opinion on drug metabolism & toxicology, vol. 9, no. 8, pp. 1025-1035. 20 17
2012	Alene, M, Wiese, MD, Angamo, MT, Bajorek, B V, Yesuf, EA & Wabe, NT 2012, 'Adherence to medication for the treatment of psychosis : rates and risk factors in an Ethiopian population', BMC clinical pharmacology, vol. 12, article no. 10. Open access 8 2
2012	Brown, SG, Wiese, MD, van, EPE, Stone, SF, Chuter, CL, Gunner, J, Wanandy, T, Phillips, M & Heddle, RJ 2012, 'Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial', Journal of allergy and clinical immunology, vol. 130, no. 1, pp. 162-168. 27 26 6
2012	Chaudhry, T, Hissaria, P, Wiese, M, Heddle, R, Kette, F & Smith, W 2012, 'Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis', Internal medicine journal, vol. 42, no. 6, pp. 665-671. 22 18 8
2012	O'Doherty, C, Schnabl, M, Spargo, L, Cleland, LG, James, M, Proudman, SM & Wiese, MD 2012, 'Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis', Pharmacogenomics, vol. 13, no. 12, pp. 1427-1434. 14 15
2012	Wiese, MD, Schnabl, M, O'Doherty, C, Spargo, LD, Sorich, MJ, Cleland, LG & Proudman, SM 2012, 'Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis', Arthritis research & therapy, vol. 14, no. 4, article no. R163, pp. 1-9. Open access 30 28 6
2012	Wiese, MD, Sluggett, JK, Wilson, CJ, Reuter, SE, Turner, SC & Evans, AM 2012, 'Perceived and actual paracetamol dosing in overweight and obese children', European journal of hospital pharmacy, vol. 19, no. 5, pp. 438-442. 1 1 4
2011	Brown, SG, Van Eeden, PE, Wiese, MD, Mullins, RJ, Solley, GO, Puy, R, Taylor, RW & Heddle, R 2011, 'Causes of ant sting anaphylaxis in Australia: the Australian ant venom allergy study', Medical journal of Australia, vol. 195, no. 2, pp. 69-73. Open access 17 15
2011	Rakhila, H, Rozek, T, Hopkins, AM, Proudman, S, Cleland, L, James, M & Wiese, M 2011, 'Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS', Journal of pharmaceutical and biomedical analysis, vol. 55, no. 2, pp. 325-331. 20 21
2011	Wiese, MD & Shahnam, H 2011, 'Current status on drug allergy', Melbourne, Australasian Pharmaceutical Pub. Co, vol. 92, no. 1098, pp. 84-88.
2011	Wiese, MD, Davies, NW, Chataway, TK, Milne, RW, Brown, SG & Heddle, RJ 2011, 'Stability of Myrmecia pilosula (Jack Jumper) ant venom for use in immunotherapy', Journal of pharmaceutical and biomedical analysis, vol. 54, no. 2, pp. 303-310. 5 5 3
2011	van Eeden, PE, Wiese, MD, Aulfrey, S, Hales, BJ, Stone, SF & Brown, SG 2011, 'Using time-resolved fluorescence to measure serum venom-specific IgE and IgG', PLoS one, vol. 6, no. 1, article no. 16741. Open access 6 6
2008	Inagaki, H, Akagi, M, Imai, HT, Taylor, R, Wiese, MD, Davies, N & Kubo, T 2008, 'Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper Ant)', Archives of Biochemistry and Biophysics, vol. 477, no. 2, pp. 411-416. 22 21 3
2008	Wiese, MD, Milne, RW, Davies, N, Chataway, T, Brown, S & Heddle, R 2008, 'Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine', Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 1, pp. 58-65. 8 8 3

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Alfred Hospital	AUSTRALIA
Australian National University	AUSTRALIA
Baker Heart and Diabetes Institute	AUSTRALIA
Beker Pharmaceuticals General Business Plc	ETHIOPIA
Bristol-Myers Squibb, US	AUSTRALIA
Centre for Eye Research Australia Ltd	AUSTRALIA
Concord Hospital	AUSTRALIA
Flinders Medical Centre	AUSTRALIA
Flinders University	AUSTRALIA
Greenslopes Private Hospital	AUSTRALIA
Jimma University	ETHIOPIA
Karolinska Institute	SWEDEN
Khon Kaen University	THAILAND
Macquarie University	AUSTRALIA
Mahidol University	THAILAND
Modbury Hospital	AUSTRALIA
Monash Medical Centre	AUSTRALIA
Monash University	AUSTRALIA
National Institute of Advanced Industrial Science and Technology	JAPAN
Projections Research	UNITED STATES
Queen Elizabeth Hospital	AUSTRALIA
Queensland University of Technology	AUSTRALIA
Repatriation General Hospital	AUSTRALIA
Royal Adelaide Hospital	AUSTRALIA
Royal Hobart Hospital	AUSTRALIA
SA Pathology	AUSTRALIA
South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC)	AUSTRALIA
Suwabus Bessouchi	JAPAN
Tokushima Bunri University	JAPAN
University of Adelaide	AUSTRALIA
University of Canberra	AUSTRALIA
University of Derby	UNITED KINGDOM
University of Manchester	UNITED KINGDOM
University of Melbourne	AUSTRALIA
University of Otago	NEW ZEALAND
University of Queensland	AUSTRALIA
University of Sheffield	UNITED KINGDOM
University of South Australia	AUSTRALIA
University of Sydney	AUSTRALIA
University of Tasmania	AUSTRALIA
University of Technology Sydney	AUSTRALIA
University of Washington	UNITED STATES
University of Western Australia	AUSTRALIA
Walter and Eliza Hall Institute of Medical Research	AUSTRALIA
Watkins Medical Centre	AUSTRALIA
Westmead Hospital	AUSTRALIA
Women's and Children's Hospital	AUSTRALIA

External engagement & recognition

Engagement/recognition	Year
Member Australian Society of Clinical Immunology and Allergy (ASCIA)	2017
Member Australian Pharmaceutical Scientists Association (APSA)	2017

Teaching & student supervision

Highlights

My primary areas of interest in teaching are oncology, rheumatology and clinical immunology. I enjoy interacting with students in small group teaching activities.

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
A computational approach to improve the prediction of fraction unbound to enhance pharmacokinetic (PK) and biopharmaceutic models	Current
Fetal and maternal drug metabolism in complicated pregnancies	Current
Novel methods of analysis and pharmacokinetics of viper venom components in human plasma	Current
Obesity and depression: a study on causality and gene-environment interactions	Current
Personalized-treatment strategies of methotrexate in rheumatoid arthritis patients	Current
Population variability of the omega-3 index and its relevance to chronic inflammatory disease states	Current
Rheumatoid arthritis is a potentially disabling form of arthritis associated with erosive joint destruction and subsequent deformity, pain and increased mortality	Current
The interaction between the effects of fetal growth on fetal drug exposure and the effects of fetal exposure on fetal growth	Current
The role of haptenation in penicillin and cephalosporin allergy	Current
Development and feasibility of a patient-centred deprescribing process	Completed
Individualisation of leflunomide dosing in rheumatoid arthritis patients	Completed
Investigating pharmacometric approaches to individualised medicine in autoimmune diseases	Completed
The role of adherence of physician to treatment strategies and patient to medications in rheumatoid arthritis	Completed

more less

Associate Professor Michael Wiese

About me

About me

School of Pharmacy and Medical Sciences

About me

Professional Associations

Experience

Qualifications

Research

Research themes

Research focus

Highlights

Projects

Outputs

Journal Articles

Current research & highlights

External engagement & recognition

Collaborations

Collaborations

External engagement & recognition

Member

Member

Teaching & student supervision

Highlights

Courses and programs

Courses I teach and/or co-ordinate

Research degree supervision

Gallery